WO2003028643A3 - Targeted therapeutic lipid constructs having cell surface targets - Google Patents

Targeted therapeutic lipid constructs having cell surface targets Download PDF

Info

Publication number
WO2003028643A3
WO2003028643A3 PCT/US2002/031090 US0231090W WO03028643A3 WO 2003028643 A3 WO2003028643 A3 WO 2003028643A3 US 0231090 W US0231090 W US 0231090W WO 03028643 A3 WO03028643 A3 WO 03028643A3
Authority
WO
WIPO (PCT)
Prior art keywords
cell surface
targeted therapeutic
lipid constructs
surface targets
therapeutic lipid
Prior art date
Application number
PCT/US2002/031090
Other languages
French (fr)
Other versions
WO2003028643A2 (en
Inventor
Charles Aaron Wartchow
John S Pease
Zhi Min Shen
Original Assignee
Targesome Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/976,254 external-priority patent/US20020071843A1/en
Application filed by Targesome Inc filed Critical Targesome Inc
Priority to AU2002362461A priority Critical patent/AU2002362461A1/en
Publication of WO2003028643A2 publication Critical patent/WO2003028643A2/en
Publication of WO2003028643A3 publication Critical patent/WO2003028643A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1217—Dispersions, suspensions, colloids, emulsions, e.g. perfluorinated emulsion, sols
    • A61K51/1234—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1217—Dispersions, suspensions, colloids, emulsions, e.g. perfluorinated emulsion, sols
    • A61K51/1234—Liposomes
    • A61K51/1237—Polymersomes, i.e. liposomes with polymerisable or polymerized bilayer-forming substances

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Novel therapeutic lipid constructs comprising a polymerized liposome, an anti-cell surface targeting agent, and a radiotherapeutic metal ion are disclosed.
PCT/US2002/031090 2001-10-01 2002-10-01 Targeted therapeutic lipid constructs having cell surface targets WO2003028643A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002362461A AU2002362461A1 (en) 2001-10-01 2002-10-01 Targeted therapeutic lipid constructs having cell surface targets

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US23631001P 2001-10-01 2001-10-01
US60/236,310 2001-10-01
US09/976,254 2001-10-11
US09/976,254 US20020071843A1 (en) 2000-10-11 2001-10-11 Targeted therapeutic agents

Publications (2)

Publication Number Publication Date
WO2003028643A2 WO2003028643A2 (en) 2003-04-10
WO2003028643A3 true WO2003028643A3 (en) 2003-10-16

Family

ID=26929660

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/031090 WO2003028643A2 (en) 2001-10-01 2002-10-01 Targeted therapeutic lipid constructs having cell surface targets

Country Status (2)

Country Link
AU (1) AU2002362461A1 (en)
WO (1) WO2003028643A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9295737B2 (en) 2002-03-01 2016-03-29 Bracco Suisse Sa Targeting vector-phospholipid conjugates
US9408926B2 (en) 2002-03-01 2016-08-09 Bracco Suisse S.A. KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US9446155B2 (en) 2002-03-01 2016-09-20 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8263739B2 (en) 2000-06-02 2012-09-11 Bracco Suisse Sa Compounds for targeting endothelial cells, compositions containing the same and methods for their use
AU2001266696A1 (en) 2000-06-02 2001-12-11 Bracco Research Usa Compounds for targeting endothelial cells
CA2439953A1 (en) * 2001-03-08 2002-09-19 Mark D. Bednarski Stabilized therapeutic and imaging agents
US7261876B2 (en) 2002-03-01 2007-08-28 Bracco International Bv Multivalent constructs for therapeutic and diagnostic applications
PL1944312T3 (en) 2003-03-03 2012-12-31 Dyax Corp Peptides that specifically bind HGF receptor (CMET) and uses thereof
WO2007052267A2 (en) * 2005-11-01 2007-05-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Biodegradable composite for internal local radiotherapy
CN103784938A (en) * 2007-02-16 2014-05-14 肿瘤疗法科学股份有限公司 Vaccine therapy for choroidal neovascularization
WO2010017325A2 (en) * 2008-08-05 2010-02-11 The Methodist Hospital Research Institute Thermally-activatable liposome compositions and methods for imaging, diagnosis and therapy
TW201109029A (en) 2009-06-11 2011-03-16 Oncotherapy Science Inc Vaccine therapy for choroidal neovascularization
TWI496583B (en) * 2012-02-15 2015-08-21 Univ Nat Chiao Tung Us of preparing pharmaceutical carrier and pharmaceutical composition for inhibiting angiogenesis
EP3288542B1 (en) 2015-04-29 2021-12-29 University Of South Australia Compositions and methods for administering antibodies

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5512294A (en) * 1994-08-05 1996-04-30 Li; King C. Targeted polymerized liposome contrast agents
US5837283A (en) * 1997-03-12 1998-11-17 The Regents Of The University Of California Cationic lipid compositions targeting angiogenic endothelial cells
US6132764A (en) * 1994-08-05 2000-10-17 Targesome, Inc. Targeted polymerized liposome diagnostic and treatment agents

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5512294A (en) * 1994-08-05 1996-04-30 Li; King C. Targeted polymerized liposome contrast agents
US6132764A (en) * 1994-08-05 2000-10-17 Targesome, Inc. Targeted polymerized liposome diagnostic and treatment agents
US5837283A (en) * 1997-03-12 1998-11-17 The Regents Of The University Of California Cationic lipid compositions targeting angiogenic endothelial cells

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9295737B2 (en) 2002-03-01 2016-03-29 Bracco Suisse Sa Targeting vector-phospholipid conjugates
US9381258B2 (en) 2002-03-01 2016-07-05 Bracco Suisse S.A. Targeting vector-phospholipid conjugates
US9408926B2 (en) 2002-03-01 2016-08-09 Bracco Suisse S.A. KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
US9446155B2 (en) 2002-03-01 2016-09-20 Bracco Suisse Sa KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy

Also Published As

Publication number Publication date
AU2002362461A1 (en) 2003-04-14
WO2003028643A2 (en) 2003-04-10

Similar Documents

Publication Publication Date Title
WO2003028643A3 (en) Targeted therapeutic lipid constructs having cell surface targets
AU2266701A (en) Antenna assembly, and associated method, having an active antenna element and counter antenna element
WO2002072011A3 (en) Stabilized therapeutic and imaging agents
AU2001236519A1 (en) Identification, assessment, prevention, and therapy of prostate cancer
WO2004029213A3 (en) Compositions and methods for delivery of short interfering rna and short hairpin rna
AU4357800A (en) Intracellular pharmaceutical targeting
AU2001249080A1 (en) Privacy-protected targeting system
AU2002349784A1 (en) Nf-kappab activating genes
AU4735200A (en) Vitamin directed dual targeting therapy
WO2000061127A3 (en) Use of insulin sensitisers for improving ketosis
AU2002953073A0 (en) Amplification of biotin-mediated targeting
AU2001292182A1 (en) Antenna transducer assembly, and an associated method therefor
WO2002096367A3 (en) Targeted multivalent macromolecules
GB9909294D0 (en) Treating hair by targeting enzymes
AU2002236062A1 (en) Lipids, lipid compositions, liposomes, and lipoplexes
WO2001095884A3 (en) Liposomal benzoquinazoline thymidylate synthase inhibitor formulations
AU7737300A (en) Dna-cleaving rnase p rna
AU2003279509A1 (en) Targeted double stranded rna mediated cell killing
AU2001250428A1 (en) Genes of the 1-desoxy-d-xylulose biosynthesis path
AU2002334891A1 (en) Tumor targeted photodiagnostic-phototherapeutic agents
AU4850300A (en) Active target wheel aligner
AU2002360525A1 (en) Targeting leukemia cells
WO2004070009A3 (en) Targeted multivalent macromolecules
AU3286500A (en) Herbicide target genes and methods
WO2002041870A3 (en) Production and use of a targeted diagnostic system

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING THE LOSS OF RIGHTS PURSUANT TO RULE 69 (1) EPC (EPO COMMUNICATION FORM 1205A DATED 03.02.2003)

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP